Glenmark Pharmaceuticals Limited (NSEI: GLENMARK)
Health Care · Pharmaceuticals · IN
Rs2,293.00
-1.63% today · +18.2% 1Y
Glenmark Pharmaceuticals Limited (NSEI: GLENMARK) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $6.69B and employs 16,946 people.
Over the last twelve months the share price has gained 18.2%, trading between 1.79K and 2.54K.
Tweenvest scores Glenmark Pharmaceuticals Limited across four factors: quality 80/100, value 37/100, growth 65/100, dividend 70/100. Its strongest factor is quality.
GLENMARK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.69B
- Revenue (TTM)
- $1.88B
- P/E
- 36.00
- EPS
- 63.69
- Dividend yield
- 0.22%
- Beta (5Y)
- 0.25
- 52-week high
- Rs2,537.60
- 52-week low
- Rs1,792.60
- Avg volume (3M)
- —
- Shares outstanding
- 282.20M
- Employees
- 16,946
- Next earnings
- —
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
- ISIN
- INE935A01035
- Founded
- 1977
- Listed since
- Jul 1, 2002
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.NasdaqGS: AMRX | $6.93B | $19.91 | +1.32% |
| Gedeon Richter PLCBUSE: RICHTER | $6.90B | Ft12,350.00 | +1.23% |
| H. Lundbeck A/SCPSE: HLUN B | $6.76B | Dkr46.48 | +1.13% |
| Ono Pharmaceutical Co., Ltd.TSE: 4528 | $6.70B | ¥2,259.00 | +0.53% |
| Alkem Laboratories LimitedNSEI: ALKEM | $6.52B | Rs5,279.00 | +1.13% |
| Belite Bio, IncNasdaqCM: BLTE | $6.22B | $154.71 | +0.14% |
| China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.SZSE: 000999 | $6.17B | CN¥24.82 | +1.39% |
| Ligand Pharmaceuticals IncorporatedNasdaqGM: LGND | $6.02B | $301.81 | -0.38% |
Figures last refreshed Oct 11, 2026.